Capital Group Investment Management’s AstraZeneca AZN Stock Holding History

Capital Group Investment Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20M	Buy	106,664 +7,651	+8%	+$1.44M	3.01%	6
2026 Q1	$19.3M	Buy	+99,013	New	+$19.1M	3.3%	6
2024 Q4	–	Sell	-4,248	Closed	-$662K	–	140
2024 Q3	$662K	Hold	4,248	–	–	0.13%	123
2024 Q2	$663K	Buy	4,248 +26	+0.6%	+$3.91K	0.14%	121
2024 Q1	$572K	Hold	4,222	–	–	0.1%	165
2023 Q4	$569K	Hold	4,222	–	–	0.06%	173
2023 Q3	$572K	Hold	4,222	–	–	0.04%	165
2023 Q2	$604K	Hold	4,222	–	–	0.03%	169
2023 Q1	$586K	Sell	4,222 -697	-14%	-$93.8K	0.03%	174
2022 Q4	$667K	Buy	+4,919	New	+$617K	0.03%	178

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Group Investment Management's AZN Position: Q2 2026 in Review

Capital Group Investment Management increased its AstraZeneca (AZN) stake by 7.7% in Q2 2026, buying an estimated $1.44M and bringing the position to 106,664 shares worth $20M. The position accounts for 3.01% of the portfolio, ranked #6.

Capital Group Investment Management first reported a position in AZN in Q4 2022 and has held it in 10 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Capital Group Investment Management held 106,664 shares of AstraZeneca worth $20M as of Q2 2026.
Capital Group Investment Management bought 7,651 AstraZeneca shares in Q2 2026, an estimated $1.44M.
AstraZeneca made up 3.01% of Capital Group Investment Management's portfolio in Q2 2026, its #6 holding.
Capital Group Investment Management first reported a position in AstraZeneca in Q4 2022 and has held it in 10 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.